Northwest Biotherapeutics (NWBO) Convertible Debt (2010 - 2026)

Northwest Biotherapeutics' Convertible Debt history runs 14 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• On a quarterly basis, Convertible Debt fell 42.4% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 42.4% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, down 67.17% from the prior year.
• Convertible Debt advanced to $7.5 million in Q1 2026 per NWBO's latest filing, from $5.2 million in the prior quarter.
• Across five years, Convertible Debt topped out at $24.6 million in Q3 2025 and bottomed at $3.8 million in Q3 2024.
• The 3-year median for Convertible Debt is $13.0 million (2025), against an average of $12.0 million.
• Biggest YoY gain for Convertible Debt was 552.28% in 2025; the steepest drop was 67.17% in 2025.
• Year by year, Convertible Debt stood at $15.9 million in 2024, then plunged by 67.17% to $5.2 million in 2025, then jumped by 43.93% to $7.5 million in 2026.
• Per Business Quant, the three latest NWBO Convertible Debt figures stand at $7.5 million (Q1 2026), $5.2 million (Q4 2025), and $24.6 million (Q3 2025).